ArticlePsychopharmacology2017
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Electroconvulsive therapy for depression and oral dyskinesia in a patient who developed parkinsonism induced by valbenazine.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia.The European journal of neuroscience · 2025Article
- Positive allosteric mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2024Article
- The mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Effect of the mGluPsychopharmacology · 2023Article
- Investigating the potential of mirtazapine to induce drug-seeking behavior in free-choice drinking mouse model.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Evaluation of the effects of the mGluPharmacological reports : PR · 2022Article
- Additive effects of mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Effect of the mGluJournal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection.Scientific reports · 2020Article
- Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Combined mGluJournal of neural transmission (Vienna, Austria : 1996) · 2020Article
- The mGluJournal of neural transmission (Vienna, Austria : 1996) · 2020Article
- Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.Biomolecules · 2019Review
- 5-HTExperimental brain research · 2019Review
- Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) psychosis is encountered in as many as 50% of patients with advanced disease. Treatment options for PD psychosis are few. In fact, only clozapine and pimavanserin have shown efficacy in randomised controlled trials. Clinicians are often reluctant to prescribe the former, due to the risk of agranulocytosis, while the latter is not widely available yet. Because it is already clinically available and exhibits high affinity for serotonin 2A receptors, a target with which both clozapine and pimavanserin interact, we hypothesised that the anti-depressant mirtazapine might be effective to alleviate PD psychosis.
methodsHere, we tested the anti-psychotic potential of mirtazapine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned common marmoset. Five MPTP-lesioned marmosets exhibiting psychosis-like behaviours were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with mirtazapine (0.1, 1 and 10 mg/kg) or vehicle. We also tested the effect of mirtazapine on L-DOPA-induced dyskinesia.
resultsThe addition of mirtazapine 10 mg/kg to L-DOPA reduced psychosis-like behaviours by 50% (P < 0.05) and dyskinesia by 29% (P < 0.01), when compared to L-DOPA/vehicle. Importantly, the antipsychotic and antidyskinetic effects of mirtazapine were achieved without hindering L-DOPA anti-parkinsonian action.
conclusionsOur results suggest that mirtazapine may be effective to alleviate PD psychosis and, because the drug is clinically available, clinical trials that would assess its anti-psychotic efficacy in PD could be rapidly undertaken, hopefully leading to a new treatment option for this debilitating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.